Stem Cells for Fertility: Why Treatment Remains Experimental
Key Takeaways
Stem-cell interventions are being studied for primary ovarian insufficiency, poor ovarian response and damaged or persistently thin endometrium. Early human studies provide research signals, especially for severe endometrial damage, but they do not establish a standard fertility treatment. Products, procedures and outcomes vary, and routine commercial use is not supported.
Key evidence: ISSCR Guidelines for Clinical Translation (2025) Systematic Review of Cellular Therapies for POI and Poor Ovarian Response (2025) Systematic Review of Stem Cells for Thin Endometrium and Asherman Syndrome (2026)
Are stem-cell treatments proven to improve fertility?
No stem-cell intervention is established as a routine fertility treatment. Research has moved beyond laboratory models in a few areas, but the evidence is still too limited and uneven to promise more eggs, better-quality embryos or a higher chance of live birth.
The phrase stem-cell treatment can also be misleadingly simple. Studies use different cell sources, manufacturing methods, doses, scaffolds and delivery routes. A result from one product or condition cannot be transferred automatically to another.
The International Society for Stem Cell Research advises that unproven cell-based interventions should remain within well-regulated research and applicable local law. Being offered commercially is not evidence that an intervention works.
What has been studied in the ovary?
Ovarian research mainly concerns primary ovarian insufficiency (POI), poor ovarian response and tissue damage after chemotherapy or radiotherapy. The question is whether a cell-based intervention can improve clinically meaningful outcomes, not simply change a laboratory marker.
A 2025 systematic review of human studies found 27 reports involving 694 participants with POI or poor ovarian response. Almost 78% of the studies had no control group, and the cell products and injection methods varied widely. Pregnancies occurred after treatment, but this evidence cannot show reliably that the intervention caused them or identify who might benefit.
Changes in AMH, follicle count or menstrual bleeding are not the same as creating new eggs or reversing age-related chromosome changes. Our guide to how egg numbers relate to IVF outcomes explains why any ovarian marker must be interpreted alongside age, embryo development and previous treatment response.
Some laboratory work is even further from patient care. A 2024 mouse study used mouse ovarian cells and mesenchymal stromal cells to construct an artificial ovary model. It helps researchers study tissue interactions; it is not evidence that an ovarian injection restores fertility in humans.
Is the evidence different for the endometrium?
There are early human data for severe intrauterine adhesions, also called Asherman syndrome, and persistently thin endometrium. The signal is worth studying, but it is not yet a routine treatment recommendation.
In a 2025 single-centre randomised trial, researchers assigned 25 women with refractory thin endometrium related to Asherman syndrome to surgery plus either a stem-cell-loaded collagen scaffold or a control scaffold. Live birth occurred in 3 of 11 women in the cell group and 1 of 13 controls. The difference was not statistically significant, and the confidence interval was very wide.
A 2026 systematic review and meta-analysis combined 18 clinical studies with 323 participants and reported improvements in endometrial thickness and reproductive outcomes. However, products, delivery routes and study designs differed. The authors concluded that large randomised trials are still needed before the approach can be recommended as effective endometrial regeneration.
This distinction matters: a promising pooled result can justify better trials without making a treatment ready for routine care.
What do the studies not establish?
Current research does not establish that stem-cell interventions:
- create new human eggs or reverse reproductive ageing;
- reliably improve embryo quality or live birth in POI or poor ovarian response;
- work as one standardised treatment across ovarian and uterine conditions;
- have known long-term safety for the recipient or a future child; or
- should replace established fertility evaluation and treatment planning.
The same caution applies to other regenerative add-ons. Ovarian PRP and exosome-based ovarian interventions are different products with different uncertainties; evidence for one cannot validate another.
What risks and burdens should be discussed?
Risk depends on the cell product and how it is delivered. Possible burdens include infection, bleeding or anaesthetic risk from an invasive procedure; immune reactions; manufacturing or contamination problems; and adverse effects that short follow-up may miss. Tumour-related testing is particularly important for some stem-cell products, but the risk cannot be generalised across every cell type.
There is also an opportunity cost. Time spent on an unproven intervention may delay an evidence-based plan, which can matter when age or ovarian reserve limits the treatment window. Fees charged outside a credible study can add financial pressure without demonstrating benefit.
How can I assess an offer or a clinical trial?
A registered study is research, not a guarantee of benefit. Before considering participation, ask for clear answers to these questions:
- What exact cell product is used, where does it come from and how is it manufactured?
- Is the study listed in a public trial registry and approved by an independent research ethics committee?
- Is there a comparison group, and is live birth a planned outcome?
- Which adverse effects are monitored, and how long will follow-up continue?
- Who pays for the intervention and for treatment if a complication occurs?
- What established options are available now, and could participation delay them?
- Which national regulator oversees the product and the procedure?
An informed-consent form is important, but it does not replace evidence. The team should explain uncertainty, alternatives and the difference between research objectives and personal clinical benefit.
Dr. Aksoy’s clinical threshold
For Dr. Aksoy, participation is reasonable only as genuine clinical research—not as a paid treatment renamed a trial. The clinical problem must first be confirmed. The international POI guideline defines POI using at least four months of irregular or absent cycles with FSH above 25 IU/L; FSH is repeated after four to six weeks when the diagnosis remains uncertain. For persistent thin endometrium, the finding should recur despite appropriate oestrogen preparation, after evaluating correctable causes such as intrauterine adhesions, a cavity lesion or suspected infection or inflammation.
The protocol should have ethics-committee and regulatory approval, a public registration, and a cell source, manufacturing process and dose that are fully described. Dr. Aksoy would also require GMP manufacturing, independent safety monitoring and long-term follow-up. A phase I study should state plainly when its main purpose is safety. If efficacy is being tested, the outcomes should extend beyond AMH or endometrial thickness to transferable embryos, ongoing pregnancy and live birth.
High charges to the participant, a guarantee of success, absent registration or oversight, or uncertainty about what the product contains are decisive red flags. Research must not consume valuable treatment time either. When follicular activity remains and eggs or embryos may still be obtained in POI, that opportunity should be protected before waiting months for an experimental intervention. When a patient already has embryos and a persistently thin endometrium, correctable causes should be addressed and a clear time limit agreed before a trial delays transfer.
He therefore discusses stem cells neither as a “last chance” nor as a substitute for established care. At most, they are a transparent research option that must not close a better-supported path. This threshold is consistent with the ISSCR clinical-translation principles.
Is routine use supported today?
No. The current evidence supports continued research, not routine commercial fertility treatment. A carefully regulated clinical trial may be reasonable for a narrowly defined group, but that decision depends on the diagnosis, trial quality, remaining established options and the cost of delaying care.
The practical starting point is still a diagnosis-based fertility assessment. Stem-cell research should not be presented as a shortcut around ovarian ageing, embryo biology or uterine disease.
FAQ
Can stem cells create new eggs?
Human clinical evidence has not shown that stem-cell treatment creates new eggs or reverses the chromosome-related effects of ovarian ageing. Changes in hormones or follicle counts do not prove either claim.
Can stem cells improve a thin endometrium?
Small studies and pooled analyses report an early signal in severe intrauterine adhesions and refractory thin endometrium. The products and procedures remain experimental, and larger randomised trials are needed to confirm live-birth benefit and long-term safety.
Are stem cells, PRP and exosomes the same treatment?
No. They differ in what is administered, how it is prepared and the risks being studied. They should not be grouped together as a single form of “ovarian rejuvenation”.
Does registration as a clinical trial mean the treatment works?
No. Registration improves transparency and allows the protocol to be checked, but the purpose of a trial is to find out whether an intervention is sufficiently safe and effective.
Sources
- International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation: Clinical Translation of Stem Cell-based Interventions, version 1.2. 2025.
- Panay N, et al.; ESHRE, ASRM, CRE-WHiRL and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065.
- Seyihoglu B, Gucuk S, Can A. Cellular therapies in primary ovarian insufficiency and poor ovarian reserve: a systematic review. Journal of Assisted Reproduction and Genetics. 2025;42(9):2837–2857. doi:10.1007/s10815-025-03599-y.
- Hou Z, et al. hUC-MSCs loaded collagen scaffold for refractory thin endometrium caused by Asherman syndrome: a double-blind randomized controlled trial. Stem Cells Translational Medicine. 2025;14(4):szaf011. doi:10.1093/stcltm/szaf011.
- Adamyan L, et al. Stem cell therapy in thin endometrium and Asherman’s syndrome: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2026;319:114949. doi:10.1016/j.ejogrb.2026.114949.
- Li J, et al. Mesenchymal stem cells promote ovarian reconstruction in mice. Stem Cell Research & Therapy. 2024;15(1):115. doi:10.1186/s13287-024-03718-z.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.